4//SEC Filing
Provost Jean-Claude 4
Accession 0000950170-24-026662
CIK 0001521036other
Filed
Mar 4, 7:00 PM ET
Accepted
Mar 5, 8:20 PM ET
Size
7.6 KB
Accession
0000950170-24-026662
Insider Transaction Report
Form 4
Provost Jean-Claude
Chief Medical Officer
Transactions
- Award
Common Stock
2024-03-01+18,564→ 39,387 total(indirect: By Theranostics Consulting SAS) - Award
Stock Option (right to buy)
2024-03-01+10,998→ 10,998 total(indirect: By Theranostics Consulting SAS)Exercise: $64.64Exp: 2034-03-01→ Common Stock (10,998 underlying)
Footnotes (2)
- [F1]Consists of 6,188 restricted stock units that vest in equal installments over a three-year period and 12,376 Total Shareholder Return performance-based restricted stock units ("PSUs") that cliff vest following a three-year performance period. The amount of PSUs included in this Report reflects the target award, however the ultimate award size can range from 0% to 200% of the target based on the actual performance achieved at the end of the performance period.
- [F2]The option vests in three equal annual installments beginning on March 1, 2025.
Documents
Issuer
Lantheus Holdings, Inc.
CIK 0001521036
Entity typeother
Related Parties
1- filerCIK 0001960060
Filing Metadata
- Form type
- 4
- Filed
- Mar 4, 7:00 PM ET
- Accepted
- Mar 5, 8:20 PM ET
- Size
- 7.6 KB